NAMS Company Profile and Key Details

NAMS has shown mixed momentum, losing -0.86% over the past week and -10.96% over the past quarter, though year-to-date performance is down -7.61%. Short-term trend indicators are bearishly aligned (SMA20 0.42%, SMA50 0.65%, SMA200 18.46%). The stock’s 14-day RSI is 49.21 (neutral), while the ATR of 1.72 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.38% below its high and over 143.81% above its low. Average 10-day trading volume of 1.06 million shares is slightly above the 3-month average of 873.99 thousand, indicating heightened recent market interest.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) closed at $29.86 USD, gaining $1.43 (5.03%) from the previous close of $28.43. The stock is currently mid-range between its 52-week high and low $16.79 and $42.00. With a market capitalization of about $3.43 billion, NewAmsterdam Pharma Company N.V. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.13). Key stats such as the average daily volume over the past year has been around 879.54 thousand shares, trading with heavier-than-usual volume. Headquartered in Naarden, None, NewAmsterdam Pharma Company N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael Harvey Davidson Facp., the company employs approximately 68 people and listed since February 09, 2021. NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.

NewAmsterdam Pharma Company N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.80. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 60.99% annually over the next five years. The latest quarter delivered EPS of -$0.63. The next quarter is forecast at -$0.49. Next year's EPS is expected at $18.66. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 8 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $52.00 to $27.00. The high target offers 74.15% upside. The low target suggests -9.58% downside. The mean target is $43.71. This offers 46.38% upside. NewAmsterdam Pharma Company N.V. earnings surprise history is a mixed track record. The quarter that ended February 18, 2026, missed forecasts by 57.5%. The prior quarter beat by 7.89%. Over the last six quarters, Apple has recorded several small beats. These include -64.0% in November 06, 2024.

NewAmsterdam Pharma Company N.V. has 114.98 million shares outstanding. The public float is 71.47 million shares, elevated short interest at 7.18% of float. This equals 6.95 million shares. The short ratio is 10.98 days. Institutional investors hold 107.32% of the float. Insiders own 0.97%. ForGrowth NAP B.V. holds 10.66 million shares, Topper James N has 3.03 million shares and Bain Capital Life Sciences Investors, LLC has 1.63 million shares. Over the past six months, insider transactions show net selling. They sold 1.13 million shares across 23 transactions.

Our AI price prediction model suggests that NewAmsterdam Pharma Company N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.7%, with price expected at $25.77 by May 18, 2026, within a range of $24.12 to $27.34 3-Month Outlook: Projected rise of 53.82%, reaching $45.93 by July 31, 2026, with a range of $44.99 to $46.82. 1-Year Outlook: Projected gain of 28.9%, with price at $38.49 by May 04, 2027, within a range of $37.08 to $40.34.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shares are flat -7.61% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NewAmsterdam Pharma Company N.V. trading at a premium to the broader market with a P/E of -16.67. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $40.91, suggesting 37.01% upside. Our AI forecast model points to short-term weakness (-13.7% over two weeks), a medium-term rise (53.82% over three months), and a longer-term gain (28.9% over one year), with expected trading ranges indicating moderate volatility.

NewAmsterdam Pharma Company N.V. trades at a P/E ratio of -16.67, slightly below the S&P 500 average, with a price-to-sales ratio of 151.75 and a price-to-book ratio of 4.97 trading at moderately above to book value. The P/FCF stands at -23.07, also below market averages.